SAN DIEGO, Feb. 28, 2017 — Medical Marijuana, Inc. (OTC PINK:MJNA), the first publicly traded cannabis company in the United States, subsidiary HempMeds® Brasil today announced that the Brazilian government approved a prescription for the Company’s cannabidiol (CBD) oil product Real Scientific Hemp Oil™ (RSHO™) to treat a patient in the country with Autism Spectrum Disorder (ASD).
This marks the first time Brazil’s National Health Surveillance Agency ANVISA has granted a prescription for RSHO™ to help an autism patient. Earlier this month, Medical Marijuana, Inc. also announced that ANVISA had also granted the filling of two separate prescriptions for RSHO™ for the first time to help a patient combat the effects of Multiple Sclerosis and Alzheimer’s disease.
“We commend the Brazilian government for its compassionate approach to cannabis and for recognizing the need for alternative treatments to treat medical conditions for which there are currently no cure,” said Chief Executive Officer of Medical Marijuana, Inc., Dr. Stuart Titus. “We hope that this most recent decision by ANVISA will bring light to additional families in Brazil who have children with autism that could benefit from access to our hemp oil. We’re optimistic about several new studies being conducted on the potential benefits of cannabis on individuals with autism, including one study being conducted in Israel focusing on CBD’s effects on behavioral symptoms associated with autism.”
ASD is a neurodevelopment disorder that develops in infancy or childhood and is characterized by social interaction difficulties, verbal and physical communication impairments, and restricted and repetitive patterns of behavior. According to the Centers for Disease Control and Prevention, 1 in 68 children in the U.S. currently have ASD. In Brazil, recent statistics suggest that 1.5 million total children have autism.
Hoping to further bring the benefits to more people suffering from autism, Mexican neurosurgeon, Dr. Saul Garza has recently mentioned that he is currently enrolling patients for a study on the effects of CBD on autism. This study comes after Dr. Garza concluded a research study on Lennox-Gastaut epilepsy in Mexico with favorable results for the botanical CBD version that is allowed into Mexico (HempMeds® RSHO-X™). These results are set to be published in the near future and formally presented at the International Epilepsy Congress in Barcelona, Spain, Sept. 2-6, 2017.
About HempMeds Brasil™
HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson’s and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil is working on additional approvals for multiple indications.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070